145 related articles for article (PubMed ID: 38758967)
21. Locoregional control and toxicity following high-dose hypofractionated and accelerated palliative radiotherapy regimens in breast cancer.
Webb K; Gothard L; Mohammed K; Kirby AM; Locke I; Somaiah N
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):e469-e477. PubMed ID: 37422360
[TBL] [Abstract][Full Text] [Related]
22. A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis.
Gil GOB; de Andrade WP; Diniz PHC; Cantidio FS; Queiroz IN; Gil MLBV; Almeida CAM; Caldeira PPR; Regalin M; Silva-Filho AL
Front Oncol; 2023; 13():1202544. PubMed ID: 37388233
[TBL] [Abstract][Full Text] [Related]
23. Decline of cosmetic outcomes following accelerated partial breast irradiation using intensity modulated radiation therapy: results of a single-institution prospective clinical trial.
Liss AL; Ben-David MA; Jagsi R; Hayman JA; Griffith KA; Moran JM; Marsh RB; Pierce LJ
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):96-102. PubMed ID: 24613813
[TBL] [Abstract][Full Text] [Related]
24. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
25. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
[TBL] [Abstract][Full Text] [Related]
26. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
27. Microbubble and ultrasound radioenhancement of bladder cancer.
Tran WT; Iradji S; Sofroni E; Giles A; Eddy D; Czarnota GJ
Br J Cancer; 2012 Jul; 107(3):469-76. PubMed ID: 22790798
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.
Nandi M; Mahata A; Mallick I; Achari R; Chatterjee S
Asian Pac J Cancer Prev; 2014; 15(6):2505-10. PubMed ID: 24761855
[TBL] [Abstract][Full Text] [Related]
30. A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer.
Yadav BS; Sharma SC
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):874-881. PubMed ID: 29485066
[TBL] [Abstract][Full Text] [Related]
31. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
32. Focused Ultrasound Stimulation of Microbubbles in Combination With Radiotherapy for Acute Damage of Breast Cancer Xenograft Model.
Sharma D; Hussein F; Law N; Farhat G; Tarapacki C; Sannachi L; Giles A; Czarnota GJ
Technol Cancer Res Treat; 2022; 21():15330338221132925. PubMed ID: 36412102
[No Abstract] [Full Text] [Related]
33. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M; Sundahl N; Kruse V; Rottey S; De Maeseneer D; Duprez F; Lievens Y; Surmont V; Brochez L; Reynders D; Danckaert W; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Ost P
JAMA Oncol; 2023 Sep; 9(9):1205-1213. PubMed ID: 37410476
[TBL] [Abstract][Full Text] [Related]
36. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
Golden EB; Chhabra A; Chachoua A; Adams S; Donach M; Fenton-Kerimian M; Friedman K; Ponzo F; Babb JS; Goldberg J; Demaria S; Formenti SC
Lancet Oncol; 2015 Jul; 16(7):795-803. PubMed ID: 26095785
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
38. MR-guided ultrasound-stimulated microbubble therapy enhances radiation-induced tumor response.
McNabb E; Sharma D; Sannachi L; Giles A; Yang W; Czarnota GJ
Sci Rep; 2023 Mar; 13(1):4487. PubMed ID: 36934140
[TBL] [Abstract][Full Text] [Related]
39. Preliminary toxicity results using partial breast 3D-CRT with once daily hypo-fractionation and deep inspiratory breath hold.
Kowalchuk RO; Romano KD; Trifiletti DM; Dutta SW; Showalter TN; Morris MM
Radiat Oncol; 2018 Jul; 13(1):135. PubMed ID: 30053864
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
